论文部分内容阅读
目的分析美沙拉嗪联合康复新液治疗溃疡性结肠炎的疗效及不良反应。方法选取医院收治的82例溃疡性结肠炎患者作为观察对象,按照随机数字表法分为对照组和观察组,每组41例,对照组给予美沙拉嗪治疗,观察组在对照组治疗的基础上联合康复新液治疗,观察比较2组的治疗效果、不良反应情况及复发率。结果观察组治疗总有效率为95.12%,高于对照组的78.05%(P<0.05);观察组复发率为9.76%,低于对照组的39.02%(P<0.01);2组不良反应发生率比较差异无统计学意义(P>0.05)。结论美沙拉嗪联合康复新液治疗溃疡性结肠炎具有临床疗效确切、安全可靠、复发率低等优势,可将其作为首选治疗方法在临床推广应用。
Objective To analyze the curative effect and adverse reactions of mesalazine combined with rehabilitation new liquid in the treatment of ulcerative colitis. Methods A total of 82 patients with ulcerative colitis admitted to the hospital were selected as observation subjects and divided into control group and observation group according to random number table method. Each group included 41 patients. The control group was treated with mesalazine and the observation group was treated with the control group On the combination of rehabilitation of new liquid treatment, observation and treatment of 2 groups were compared, adverse reactions and recurrence rate. Results The total effective rate of the observation group was 95.12%, which was higher than that of the control group (78.05%, P <0.05). The recurrence rate of the observation group was 9.76%, which was lower than that of the control group (39.02%, P <0.01) The difference was not statistically significant (P> 0.05). Conclusion Mesalazine combined with Kangfuxin solution has the advantages of definite curative effect, safe and reliable, low recurrence rate and so on. It can be used as the first choice for clinical treatment in patients with ulcerative colitis.